Researchers published new findings that deepen understanding of neurotoxic effects associated with CAR‑T cell therapies. The work dissects mechanistic drivers of neurotoxicity and identifies biomarkers and potential intervention points to mitigate neurologic adverse events. Authors propose monitoring strategies and therapeutic approaches that could refine patient selection and management during CAR‑T treatment. The results are relevant to developers, clinicians and regulators working to broaden CAR‑T indications while improving safety profiles.